pharma · Hepatocellular Carcinoma · Liver Cancer
Chinese PLA General
Chinese PLA General Hospital
Chinese PLA General clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- CN
- Programs
- 4
- Drugs
- 9
- Patents
- 0
Chinese PLA General projects
4 ClinicalTrials.gov programs sponsored by Chinese PLA General.
Chinese PLA General has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Chemotherapy drug
Chinese PLA General Hospital
Gastric Cancer
1 trial -
adoptive immunotherapy
Chinese PLA General Hospital
Hepatocellular Carcinoma
1 trial -
anti-CD133-CAR vector-transduced T cells
Chinese PLA General Hospital
Liver Cancer
1 trial -
raltitrexed combined with apatinib
Chinese PLA General Hospital
Colorectal Cancer
1 trial
Frequently asked questions
How many clinical projects does Chinese PLA General have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.